Roche ’s OCREVUS (ocrelizumab) approved in Switzerland for primary progressive and relapsing forms of multiple sclerosis

Roche announced today that the Swiss agency for the authorisation and supervision of therapeutic products (Swissmedic) has granted authorisation of OCREVUS ® (ocrelizumab) for the treatment of adult patients with active relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news